CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 11, 2006--Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company
overview at the BIO InvestorForum 2006 on October 18, 2006 at 1:40
p.m. (PT) at The Palace Hotel, San Francisco, California.
A live audio webcast of these presentations will be available on
the "Investors" section of the company's website, www.alnylam.com. A
replay of the presentations will be posted on the Alnylam website
approximately three hours after each event, and will be archived for
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
applying its therapeutic expertise in RNAi to address significant
medical needs, many of which cannot effectively be addressed with
small molecules or antibodies, the current major classes of drugs.
Alnylam is building a pipeline of RNAi therapeutics; its lead program
is in Phase I human clinical trials for the treatment of respiratory
syncytial virus (RSV) infection, which is the leading cause of
hospitalization in infants in the U.S. The company's leadership
position in fundamental patents, technology, and know-how relating to
RNAi has enabled it to form major alliances with leading companies
including Merck, Medtronic, Novartis, and Biogen Idec. The company,
founded in 2002, maintains global headquarters in Cambridge,
Massachusetts, and has an additional operating unit in Kulmbach,
Germany. Alnylam is honored to be the "emerging/mid-cap" company
recipient of the 2006 James D. Watson Helix Award, the biotechnology
industry's award for outstanding achievement. For more information,
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Kathryn Morris, 845-635-9828
SOURCE: Alnylam Pharmaceuticals, Inc.